Gritstone Bio Inc (NAS:GRTS)

$ 0.7733 0.0267 (3.58%) Market Cap: 83.96 Mil Enterprise Value: 138.04 Mil PE Ratio: 0 PB Ratio: 5.52 GF Score: 50/100

Gritstone bio Inc at Goldman Sachs Catalyst Clinic (Virtual) Transcript
Dec 05, 2023
Gritstone bio Inc at Goldman Sachs Healthcare Conference Transcript
Jun 12, 2023
Q1 2023 Gritstone bio Inc Earnings Call Transcript
May 11, 2023

$2.61 (-1.51%)

Earnings
Q4 2022 Gritstone bio Inc Earnings Call Transcript
Mar 09, 2023

$2.31 (-2.94%)

Earnings
Gritstone bio Inc at B Riley Securities Oncology Conference (Virtual) Transcript
Jan 19, 2023
Gritstone bio Inc at JPMorgan Healthcare Conference Transcript
Jan 12, 2023
Gritstone bio Inc CORAL Data Update and samRNA for Infectious Diseases Call Transcript
Oct 25, 2022
Q2 2022 Gritstone bio Inc Earnings Call Transcript
Aug 04, 2022

$3.4 (+21.43%)

Earnings
Gritstone bio Inc Shareholder Q&A Session Presentation Transcript
May 11, 2022
Gritstone bio Inc at JPMorgan Healthcare Conference Transcript
Jan 13, 2022
Gritstone bio Inc to Discuss the Results from First Cohort of CORAL-BOOST Study- Conference Call Transcript
Jan 04, 2022
Gritstone bio Inc Data Update on Neoantigen Oncology Programs (GRANITE & SLATE) - Conference Call Transcript
Sep 17, 2021
Gritstone bio Inc Key Opinion Leader Webinar on Neoantigen Oncology Programs Transcript
Aug 18, 2021
Gritstone bio Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 10, 2021
Gritstone Oncology, Inc. - Special Call Transcript
Jan 19, 2021
Gritstone Oncology Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 14, 2021
Gritstone Oncology Inc Investor Event to Present Phase 1 GRANITE and SLATE Data Transcript
Jul 13, 2020
Gritstone Oncology Inc Annual Shareholders Meeting Transcript
Jun 18, 2020
Gritstone Oncology Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 10, 2020
Gritstone Oncology Inc at Barclays Global Healthcare Conference Transcript
Mar 11, 2020
Gritstone Oncology Inc at JPMorgan Healthcare Conference Transcript
Jan 16, 2020
Gritstone Oncology Inc ESMO-IO Investor Meeting Transcript
Dec 12, 2019
Gritstone Oncology Inc Corporate Investor Event at Society for Immunotherapy of Cancer (SITC) Conference Transcript
Nov 08, 2019

Gritstone Oncology Inc Investor Event to Present Phase 1 GRANITE and SLATE Data Transcript

Jul 13, 2020 / 12:00PM GMT

Release Date Price: $4.02 (-50.31%)

Transcript

Operator

Welcome to the Gritstone Conference Call. My name is John. I'll be your operator for today's call. (Operator Instructions). I will now turn the call over to Dr. Andrew Allen, President and CEO of Gritstone.

Andrew R. Allen

Gritstone Oncology, Inc. - Co-Founder, President, CEO & Director

Thank you. Good morning, everybody. Welcome to the Gritstone Oncology midyear clinical data update and discussion of our near-term Phase II plans. This morning, I'll be making some forward-looking statements, and we hope you're going to enjoy the next 1.25 hours. I'll be setting up the presentation today describing briefly the background to our 2 neoantigen directed therapeutics, GRANITE and SLATE. And then it's my great pleasure to hand over to Dr. Daniel Catenacci, who is Head of GI Oncology at the University of Chicago and one of our principal investigators. And Dan will present to you the Phase I clinical trial data that we have so far off of these programs, both of which he's very closely involved with. Then I will pick up, and will present to you the near-term Phase II

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.